AnGes

Focus: AnGes is a Japan-based biotechnology company specializing in gene therapy, with a public listing and a focused pipeline in vascular and degenerative diseases. The company operates as a mid-cap biotech with early-to-mid stage clinical programs.

Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About AnGes

AI assessmentNot Hiring

No open roles listed right now. Follow AnGes to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Subjects from Study AG-CLI-0206 who received AMG0001

Critical Limb Ischemia

N/A

Clinical Trials (1)

NCT02974179A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia

N/A

Help build intelligence for AnGes

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead role in emerging gene therapy space with 11 active clinical trials across multiple indications
Opportunity to contribute to Phase 3 advancement of hepatocyte growth factor plasmid for Critical Limb Ischemia, a major unmet need
Japan-based biotech with public capital structure provides stability and international growth trajectory

Watch Out For

Zero active job postings signal current hiring freeze or minimal expansion despite clinical progress
Limited public financial data (no revenue, R&D spend, or cash position disclosed) raises transparency concerns for long-term stability assessment

Generated by Claude from AnGes's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

AMG0103

Degenerative Disc Disease

Phase 1

Clinical Trials (1)

NCT03263611AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain

Phase 1

AG0301-COVID19

COVID-19

Phase 1/2

Clinical Trials (1)

NCT04463472Study of COVID-19 DNA Vaccine (AG0301-COVID19)

Phase 1/2

HGF plasmid

Arterial Occlusive Disease

Phase 2

Clinical Trials (1)

NCT00189540Study of Hepatocyte Growth Factor (HGF) Via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Patients With Peripheral Ischemic Ulcers

Phase 2

AMG0001

Peripheral Artery Disease

Phase 2

Clinical Trials (1)

NCT04267640Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

Phase 2

HGF Plasmid

Critical Limb Ischemia

Phase 2

Clinical Trials (1)

NCT02016755A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia